Insulin medicines: Use case
Use cases
Each use, its share of demand and volume, how critical the product is to it and why, and the price paid
| Use case | Volume | Unit | Criticality | Reason | Year | Source |
|---|---|---|---|---|---|---|
| People with type 1 diabetes (world, WHO 2021) | 9 million | people | Essential | WHO: people with type 1 diabetes need insulin injections for survival. | 2021 | [1][2] |
| People with type 2 diabetes for whom insulin is essential (world, WHO 2021, more than) | 60 million | people | Essential | WHO says insulin is essential for them; one in two of those who need it do not get it. | 2021 | [1] |
| People on insulin therapy in India (type 1 and type 2, as reported) | 6 million | people | Essential | These patients are on insulin therapy; Novo Nordisk expects 9 million users in the near future, the article says. | 2026 | [10] |
as of 2026-11-13
Industries that buy it
The industries and kinds of firm that buy it, for which use case, and how critical it is to them
Used by- Healthcare services Treatment of diabetes · criticality essential Clinics, hospitals and pharmacies supply insulin to patients, who inject it themselves; no share found.
as of 2026-11-13
How it is used
Lifetime, use per year and utilisation, by variant
| Measure | Value | Unit | Place | Year | Source |
|---|---|---|---|---|---|
| Pens used per patient in a year, once-daily basal insulin (modelled by authors from Novo Nordisk and Putnam) | 22 | pens per year | France | 2024 | [14] |
| Pens used per patient in a year, once-weekly basal insulin (modelled by authors from Novo Nordisk and Putnam) | 5 | pens per year | France | 2024 | [14] |
| People on insulin therapy (as reported in the press, roughly) | 6 | million people | India | 2026 | [10] |
| People living with diabetes, all types and treatments | 830 | million people | World | 2022 | [2] |
as of 2026-11-13
Prices
Unit prices by market or use, with year and source
| Market | Value | Unit | Year | Source |
|---|---|---|---|---|
| US manufacturer gross price per 100 IU as a multiple of the price in 33 OECD comparison countries combined | 9.71 | times | 2022 | [9] |
| US net price per 100 IU after estimated gross-to-net discounts, as a multiple of the price in the comparison countries combined | 2.33 | times | 2022 | [9] |
| Analogue insulins against human insulins, at least (WHO; in some countries three times) | 1.5 | times the price | 2021 | [1] |
| Biosimilar insulins against the originator product, could be cheaper by more than | 25 | % | 2021 | [1] |
| Awiqli (once-weekly insulin), 1 ml pen, India (as reported by BioSpectrum India; not confirmed from an official price list) | 2611 | INR | 2026 | [10] |
| Awiqli, 3 ml pen, India (as reported by BioSpectrum India; not confirmed from an official price list) | 7833 | INR | 2026 | [10] |
| Once-weekly 70-unit dose of Awiqli, India, against Rs 345 to Rs 453 for 70 units of daily basal insulin (the company's own comparison, as reported) | 261 | INR | 2026 | [10] |
as of 2026-11-13
Sources
- New WHO report maps barriers to insulin availability and suggests actions to promote universal access World Health Organization, 2021, news item of 12 November 2021
- Diabetes (fact sheet) World Health Organization, 2026, fact sheet dated 11 November 2026
- Comparing Insulin Prices in the United States to Other Countries: Updated Results Using 2022 Data RAND Health Quarterly (Andrew W. Mulcahy and Daniel Schwam), 11(3):3, 2024, abstract and summary
- India 2030: Who Supplies the Next 10 Million? BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
- Environmental Impact of Switching from Daily to Weekly Basal Insulin Administration in France ISPOR Europe 2024 abstract EE212 (Bellier L, Antier C, Soggiu M, Virely N, Laporte L, Sivignon M, Kind B; affiliations Putnam, Paris, and Novo Nordisk, Paris), Value in Health 27(12) S2, 2024